Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek® and ELISA.

Abstract

AIM:

To compare nuclear matrix protein 22 expression by BladderChek® and ELISA, as urine-based assays for bladder cancer (BC) detection.

PATIENTS AND METHODS:

Urine samples of 100 BC patients and 100 controls were analyzed. Comparative statistical evaluations were based on sensitivity and specificity.

RESULTS:

Seventy-one patients had primary and 29 recurrent BC. The sensitivity of BladderChek® was significantly higher compared to ELISA in the overall cancer cohort and in patients with primary BC (p<0.0001 and p=0.0001, respectively). Both tests demonstrated significant correlation of sensitivities and tumor stage/grade for the overall cancer cohort and for patients with primary BC. Both tests had specificity values of 100% in healthy individuals. Specificity was 93% for BladderChek® and 99% for ELISA in patients with benign diseases (p=0.048).

CONCLUSION:

BladderChek® may be clinically more useful for BC detection. Due to high specificity, BladderChek® could be used for high-risk screening. However, due to its low sensitivity, BladderChek® cannot replace but only complement cystoscopy for BC detection.

• Authors: Georgios Hatzichristodoulou, Hubert Kübler, Hartwig Schwaibold, Stefan Wagenpfeil, Cornelia Eibauer, Christian Hofer, Jürgen Gschwend, Uwe Treiber
• Journal: Anticancer research (Anticancer Res) Vol. 32 Issue 11 Pg. 5093-7 (Nov 2012) ISSN: 1791-7530 [Electronic] Greece
• PMID: 23155286 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Biomarkers, Tumor
• Nuclear Proteins
• nuclear matrix protein 22

Topics

• Aged
• Biomarkers, Tumor (urine)
• Carcinoma, Transitional Cell (diagnosis, urine)
• Case-Control Studies
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Grading
• Neoplasm Staging
• Nuclear Proteins (urine)
• Point-of-Care Systems
• Sensitivity and Specificity
• Urinary Bladder Neoplasms (diagnosis, urine)